Know Cancer

or
forgot password

Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans


N/A
18 Years
65 Years
Open (Enrolling)
Both
DLBCL

Thank you

Trial Information

Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans


Inclusion Criteria:



- DLBCL or Healthy blood donors or septic patient or GOELAMS 075 patients in completed
remission

- Written informed consent

Exclusion Criteria:

- Age < 18 or > 65

- Not written informed consent

- Not affiliated with social security

Type of Study:

Observational

Study Design:

Observational Model: Cohort

Outcome Measure:

Research for cancer-related biomarkers

Outcome Description:

In this project we propose two complementary approaches with a first one orientated to the continuum of our current findings based on genes differentially expressed in blood between DLBCL patients and healthy people and a second one which takes in account the power and originality of our 075 GOELAMS cohort and will be focused on the research of predictive signatures of the DLBCL. We will go beyond the sole transcriptomic approach and also look for relevant cell biology clues.

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Thierry Fest, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Rennes University Hospital

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

2010-A00812-37

NCT ID:

NCT01287923

Start Date:

February 2010

Completion Date:

February 2014

Related Keywords:

  • DLBCL
  • Hematology
  • Secondary lymphoid organs
  • Lymphoma

Name

Location